Tharimmune, Inc.
THARNASDAQ
Healthcare
Biotechnology
$3.29
+0.21(6.8%)
52W $1.05 – $7.71
Operating Income was -$20.1M (-61.7%) Net Income was -$35.9M (-194.5%) Eps was $-1.12 (88.1%)
$130MMkt Cap
—Rev TTM
-$48MNI TTM
-2.0xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 30, 2026Operating Income was -$20.1M (-61.7%) Net Income was -$35.9M (-194.5%) Eps was $-1.12 (88.1%)
What Changed Recently
Fundamentals
How The Business Makes Money
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Industry Biotechnology
Company Profile
CIK0001861657
ISINUS4327053090
CUSIP432705200
Phone732 889 3111
Address34 Shrewsbury Avenue, Bridgewater, NJ, 07701, US
SEC EDGAR